BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26486739)

  • 1. Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.
    Mehrotra M; Luthra R; Singh RR; Barkoh BA; Galbincea J; Mehta P; Goswami RS; Jabbar KJ; Loghavi S; Medeiros LJ; Verstovsek S; Patel KP
    Am J Clin Pathol; 2015 Nov; 144(5):746-55. PubMed ID: 26486739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of CALR mutation testing for clinical diagnosis.
    Maier CL; Fisher KE; Jones HH; Hill CE; Mann KP; Zhang L
    Am J Clin Pathol; 2015 Nov; 144(5):738-45. PubMed ID: 26486738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis.
    Jeong JH; Lee HT; Seo JY; Seo YH; Kim KH; Kim MJ; Lee JH; Park J; Hong JS; Park PW; Ahn JY
    Ann Lab Med; 2016 Jul; 36(4):291-9. PubMed ID: 27139600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
    Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
    BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
    Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
    Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
    Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
    Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Allele-specific polymerase chain reaction and electrophoretic detection in the detection algorithm clinically significant somatic mutations in the gene of calreticulin (calr).].
    Gorbenko AS; Stolyar MA; Olkhovskiy IA; Abdullaev AO; Sudarikov AB; Dunaeva EA; Mironov KO; Shipulin GA
    Klin Lab Diagn; 2018; 63(9):588-592. PubMed ID: 30735328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
    Belcic Mikic T; Pajic T; Sever M
    Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
    Ha JS; Kim YK
    Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
    Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
    Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
    Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED
    Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAPID LOW-COST DETECTION OF TYPE 2CALR MUTATION BY ALLELE-SPECIFIC RT-PCR FOR DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS.
    Dybkov MV; Zavelevich MP; Gluzman DF; Telegeev GD
    Exp Oncol; 2022 May; 44(1):83-86. PubMed ID: 35548965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calreticulin Mutations in Bulgarian MPN Patients.
    Pavlov I; Hadjiev E; Alaikov T; Spassova S; Stoimenov A; Naumova E; Shivarov V; Ivanova M
    Pathol Oncol Res; 2018 Jan; 24(1):171-174. PubMed ID: 28411309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
    Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
    Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
    Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
    Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformation sensitive gel electrophoresis for the detection of calreticulin mutations in BCR-ABL1-negative myeloproliferative neoplasms.
    Zakaria NA; Rosle NA; Siti Asmaa MJ; Aziee S; Haiyuni MY; Samat NA; Husin A; Hassan R; Ramli M; Mohamed Yusoff S; Ibrahim IK; Al-Jamal HAN; Johan MF
    Int J Lab Hematol; 2021 Dec; 43(6):1451-1457. PubMed ID: 34125992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel assay to detect calreticulin mutations in myeloproliferative neoplasms.
    Rosso V; Petiti J; Bracco E; Pedrola R; Carnuccio F; Signorino E; Carturan S; Calabrese C; Bot-Sartor G; Ronconi M; Serra A; Saglio G; Frassoni F; Cilloni D
    Oncotarget; 2017 Jan; 8(4):6399-6405. PubMed ID: 28031530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
    Martin S; Wright CM; Scott LM
    Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
    Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
    Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.